¼±Åà - È­»ìǥŰ/¿£ÅÍŰ ´Ý±â - ESC

 
"contact receptor"¿¡ ´ëÇÑ °Ë»ö °á°úÀÔ´Ï´Ù. °Ë»ö °á°ú º¸´Â µµÁß¿¡ Tab ۸¦ ´©¸£½Ã¸é °Ë»ö âÀÌ ¼±Åõ˴ϴÙ.
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • paciniform receptor
    ÆÄÄ¡´ÏÇü¼ö¿ë±â
  • progesterone receptor
    ÇÁ·Î°Ô½ºÅ׷мö¿ëü
  • receptor
    1. ¼ö¿ëü 2. ¼ö¿ë±â
  • receptor autoradiography
    ¼ö¿ëüÀÚ°¡Á¶Á÷¹æ»ç¼±ÃÔ¿µ(¼ú)
  • receptor binding
    ¼ö¿ëü°áÇÕ
  • receptor blocker
    ¼ö¿ëüÂ÷´ÜÁ¦
  • receptor cell
    ¼ö¿ëü¼¼Æ÷
  • receptor destroying enzyme
    ¼ö¿ëüÆÄ±«È¿¼Ò
  • receptor gradient
    ¼ö¿ë´Ü¹é±â¿ï±â, ¼ö¿ë´Ü¹é°æ»ç, ¼ö¿ëü°æ»ç
  • receptor imaging
    1. ¼ö¿ëü¿µ»ó 2. ¼ö¿ëü¿µ»óÈ­
  • receptor internalization
    ¼ö¿ëü³»ÀçÈ­
  • receptor potential
    ¼ö¿ëüÀüÀ§
  • receptor site
    ¼ö¿ëüºÎÀ§
  • receptor stimulant
    ¼ö¿ëüÀÚ±ØÁ¦
  • receptor supersensitivity
    ¼ö¿ëüÃʹΰ¨¼º
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • kinesthetic receptor
    ¿îµ¿°¨°¢¼ö¿ëü
  • labyrinthine receptor
    ¹Ì·Î¼ö¿ëü
  • muscarinic receptor
    ¹«½ºÄ«¸°¼ö¿ëü
  • neuromuscular receptor
    ½Å°æ±ÙÀ°¼ö¿ëü
  • nicotinic receptor
    ´ÏÄÚÆ¾¼ö¿ëü
  • olfactory receptor
    Èİ¢¼ö¿ëü
  • opiate receptor
    ¾ÆÆí¼ö¿ëü
  • opioid receptor
    ¾ÆÆíÀ¯»ç¹°Áú¼ö¿ëü
  • paciniform receptor
    ÆÄÄ¡´ÏÇü¼ö¿ëü
  • postsynaptic receptor
    ¿¬Á¢Èļö¿ëü
  • prejunctional neuromuscular receptor
    ½Å°æ±ÙÀ°Á¢ÇÕÀü¼ö¿ëü
  • pressor receptor
    ¾Ð·Â¼ö¿ëü
  • receptor potential
    °¨¼ö±âÀüÀ§, °¨¼ö±âÀü¾Ð, ¼ö¿ëüÀü¾Ð
  • receptor
    ¼ö¿ëü, ¼ö¿ë±â
  • receptor site
    ¼ö¿ëüºÎÀ§
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
  • alpha-adrenal receptor antagonist
    ¾ËÆÄ ¾Æµå·¹³¯¸°¼ö¿ëüÂ÷´ÜÁ¦
  • alpha-adrenergic receptor
    ¾ËÆÄ-¾Æµå·¹³¯¸°¼ö¿ëü.
  • alpha-adrenergic receptor
    ¾ËÆÄ¾Æµå·¹³¯¸°¼ö¿ëü
  • androgen receptor
    ³²¼ºÈ£¸£¸ó ¼ö¿ëü
  • antigen binding receptor
    Ç׿ø°áÇÕ¼ö¿ëü
  • antigen receptor
    Ç׿ø¼ö¿ëü.
  • benzodiazepine receptor agonists(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ÀÛ¿ëÁ¦
  • benzodiazepine receptor antagonist(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü ±æÇ×Á¦
  • benzodiazepine receptor(s)
    º¥Á¶´ÙÀ̾ÆÁ¦ÇÉ ¼ö¿ëü
  • beta adrenergic receptor
    º£Å¸¾Æµå·¹³¯¸°¼º ¼ö¿ëü(¼ö¿ë±â, °¨¼öü)
  • beta receptor
    º£Å¸ ¼ö¿ëü(¼ö¿ë±â, °¨¼öü, °¨¼ö±â)
  • beta receptor blocker
    º£Å¸¼ö¿ëü Â÷´ÜÁ¦( -áôé»ô÷ ó´Ó¨ð¥)
  • beta receptor stimulating agent
    º£Å¸¼ö¿ëü ÀÚ±ØÁ¦( -áôé»ô÷ í©Ð½ð¥)
  • beta-ARK : beta-adrenergic receptor kinase
    º£Å¸-¾Æµå·¹³¯¸°(¼º)¼ö¿ëü ÀλêÈ­È¿¼Ò.
  • beta-adrenergic receptor
    º£Å¸ ¾Æµå·¹³¯¸°¼º ¼ö¿ëü
KMLE ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
CR calculation rate; calculus removed; calorie-restricted; cardiac rehabilitation; cardiac resuscitatio...
CRL cell repository line; Certified Record Librarian; complement receptor location; complement receptor ...
DR degeneration reaction; delivery room; deoxyribose; diabetic retinopathy; diagnostic radiology; digit...
ERA electrical response activity; electroencephalic response audiometry; Electroshock Research Associati...
ERP early receptor potential; effective refractory period; elodoisin-related peptide; endoscopic retrogr...
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü À¯»ç °Ë»ö °á°ú : 5 ÆäÀÌÁö: 6
R,S receptor agonist
8-OH-DPAT 5-HT(1A) receptor agonist, 8-hydroxy 2(di-n-propyl(amino)tetralin
5-HT3R 5-HT)3 receptor
67 LR 67 kDa laminin receptor
A(1)AR A(1) adenosine receptor
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
  • posterior contact
    ±¸Ä¡ºÎ Á¢ÃË
  • premature contact
    Á¶±â Á¢ÃË
  • protrusive contact
    Àü¹æ Á¢ÃË
  • proximal contact area
    ÀÎÁ¢¸é Á¢ÃË ºÎÀ§
  • reciprocating incline contact
    ´ëÇâ ±³µÎ »ç¸é Á¢ÃË
  • retruded contact
    ÈĹæ Ä¡¾Æ Á¢ÃË, ÈĹæ Á¢ÃË
    ÈĹæÀ¸·Î º¯À§µÈ Æó±¸·Î¸¦ µû¸¥ Ä¡¾ÆÀÇ Á¢ÃË.
  • single contact
    ´ÜÀÏ Á¢ÃË
  • single posterior tooth contact
    ´ÜÀÏ ±¸Ä¡ Á¢ÃË
  • synaptic contact
    ½Ã³À½º Á¢ÃË
  • tooth-contact relation change
    Ä¡¾Æ Á¢ÃË °ü°è º¯È­
  • toric contact lens
    ³­½Ã ÄÜÅÃÆ®·»Áî
  • unassisted mediotrusive contact
    ºñº¸Á¶ ³»Ãø¹æ Á¢ÃË
  • valve contact
    ÆÇ¸·ÀÇ ºÎÂøÁö
  • working occlusal contact
    ÀÛ¾÷Ãø ±³ÇÕ Á¢ÃË
    ÇϾÇÀÇ À¯µµµÈ Ãø¹æ ¿îµ¿ µ¿¾È µ¿Ãø¿¡¼­ ÀϾ´Â Ä¡¾Æ Á¢ÃË.
  • working posterior contact
    ÀÛ¾÷Ãø ÈĹæ Á¢ÃË
CancerWEB ¿µ¿µ ÀÇÇлçÀü À¯»ç °Ë»ö °á°ú : 15 ÆäÀÌÁö: 6
receptor protein An intracellular protein (or protein fraction) that has a high specific affinity for binding a known stimulus to cellular activity, such as a steroid hormone or adenosine 3',5'-cyclic phosphate.
(05 Mar 2000)
receptor protein-tyrosine kinase <enzyme> A catalytic protein-tyrosine kinase domain found on the cytoplasmic beta-portion of receptors. Many growth and differentiation factor receptors contain this domain. It is critical for the signal transduction pathways required for mitogenesis, transformation, and cell differentiation.
Registry number: EC 2.7.1.-
(12 Dec 1998)
receptor site Point of attachment of viruses, hormones, or other activators to cell membranes.
(05 Mar 2000)
receptor tyrosine kinase Class of membrane receptors that phosphorylate tyrosine residues. Many play significant roles in development or cell division.
Examples: insulin receptor family, c ros receptor, Drosophila sevenless, trk family.
(18 Nov 1997)
receptor, visual The layer of rods and cones, the visual cells, of the retina.
(12 Dec 1998)
Cek4 receptor protein-tyrosine kinase <enzyme> Isolated from mouse and chicken.
Registry number: EC 2.7.1.-
Synonym: cek4 protein, cek4 eph receptor, eph receptor cek4
(26 Jun 1999)
visual receptor cells The rod and cone cell's of the retina.
(05 Mar 2000)
glutamate receptor <physiology> See amino acid receptor superfamily. Glutamate receptors are implicated in many important brain functions including long-term potentiation (LTP).
at least 4 major glutamate gated ion channel subtypes are presently distinguished on pharmacological grounds, named after their most selective agonists: N methyl D aspartate (NMDA implicated in memory and learning, neuronal cell death, ischaemia and epilepsy), kainic acid (KA), quisqualate/AMPA and L 2 amino 4 phosphobutyrate (APB). A fifth subtype (APCD) trans 1 amino cyclopentane 1,3 dicarboxylate is a G-protein coupled receptor.
(18 Nov 1997)
glycine receptor <physiology> Chloride channel forming receptor. One of a family of neurotransmitter receptors with fast intrinsic ion channels.
See: amino acid receptors.
(18 Nov 1997)
peptide receptor Specific receptor for peptide neurotransmitters.
(18 Nov 1997)
G-protein coupled receptor <cell biology> Cell surface receptors that are coupled to G-proteins (GTP-binding protein).
G-protein coupled receptors are thought to have seven membrane spanning domains and have been divided into 2 subclasses: those in which the binding site is in the extracellular domain for example receptors for glycoprotein hormones, such as thyroid stimulating hormone (TSH) and follicle-stimulating hormone (FSH) and those in which the ligand binding site is likely to be in the plane of the 7 transmembrane domains for example rhodopsin and receptors for small neurotransmitters and hormones for example muscarinic acetylcholine receptor.
(18 Nov 1997)
chemokine receptor A molecule that receives a chemokine and a chemokine dock. Several chemokine receptors are essential co-receptors for HIV.
(12 Dec 1998)
metabotropic receptor A type of receptor that is linked to intracellular production of 1,2-diacylglycerol and inositol 1,4,5-trisphosphate.
Origin: metabolism + G. Trope, turning, inclination, + -ic
(05 Mar 2000)
ryanodine receptor calcium release channel Protein complexes that mediate the release of calcium from the sarcoplasmic reticulum in both skeletal and cardiac muscle cells by forming tetrametric complexes. These complexes each then act as a calcium channel. There are three isoforms of the ryr: ryr1, ryr2, and ryr3. Ryr1 is specifically expressed in skeletal muscles and ryr2 in cardiac muscles. Ryr3 is yet another isoform found in non-muscle cells such as neuronal cells.
(12 Dec 1998)
PL7a receptor-tyrosine kinase <enzyme> A member of the eph receptor tyrosine kinase subfamily; shows 80% identity with myk-1; genbank l43622
Registry number: EC 2.7.1.-
Synonym: pl7a protein
(26 Jun 1999)
ÀÌ ¾Æ·¡ ºÎÅÍ´Â °á°ú°¡ ¾ø½À´Ï´Ù.
KMLE ¾àǰ/ÀǾàǰ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
KMLE ¾àǰ/ÀǾàǰ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • Á¦Ç°¸í
    ¼ººÐ/ÇÔ·®
    ±¸ºÐ/º¸Çè±Þ¿©
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¾Ë±â½¬¿î ÀÇÇпë¾îÇ®ÀÌÁý, ¼­¿ïÀÇ´ë ±³¼ö ÁöÁ¦±Ù, °í·ÁÀÇÇÐ ÃâÆÇ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÀÇÇù Çʼö ÀÇÇпë¾îÁý »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 2 ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
¿¾ ´ëÇÑÀÇÇù 3 ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑÇØºÎÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѽŰæ¿Ü°úÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ÇÑÀÚ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇѱâ»ýÃæÇÐȸ ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
´ëÇÑ»ýÈ­ÇкÐÀÚ»ý¹°ÇÐȸ ¿ë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KI ÀÇÇпë¾î »çÀü °Ë»ö À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
KMLE ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE ÀÚµ¿ÃßÃâ ÀÇÇоà¾î »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÀÇÇÐ³í¹® ¾àÀÚ(Pubmed/Entrez) °Ë»ö ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
Çѱ¹Ç¥ÁØÁúº´»çÀκзù ¾àÀÚ À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ÄÚµå
    ¿µ¹®
    ÇѱÛ
°æºÏ´ë Ä¡°ú´ëÇÐ ±¸°­³»°ú ±³½Ç »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
    ¼³¸í
CancerWEB ¿µ¿µ ÀÇÇлçÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
MeSH(Medical Subject Headings) À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü ¸ÂÃã °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Merriam-Webster's ÀÇÇлçÀü À¯»ç °Ë»ö (https://www.merriam-webster.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - A.D.A.M. Medical Encyclopedia À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics ¸ÂÃã °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - MedlinePlus Health Topics À¯»ç °Ë»ö (http://www.nlm.nih.gov) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ ¸ÂÃã °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - µå·¯±×ÀÎÆ÷ ¾àÇÐ Á¤º¸ À¯»ç °Ë»ö (http://www.druginfo.co.kr) °á°ú: 0 ÆäÀÌÁö: 6
Á¦Ç°¸í
ÆÇ¸Å»ç
º¸ÇèÄÚµå ¼ººÐ/ÇÔ·®
±¸ºÐ/º¸Çè±Þ¿©
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference ¸ÂÃã °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - WebMD.com Drug Reference À¯»ç °Ë»ö (http://www.webmd.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition ¸ÂÃã °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - Drug.com Drugs by Medical Condition À¯»ç °Ë»ö (http://www.drugs.com) °á°ú: 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
KMLE À¥ ¿ë¾î À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
ÇÑ¿µ/¿µÇÑ »çÀü ¸ÂÃã °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
ÇÑ¿µ/¿µÇÑ »çÀü À¯»ç °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
  • ¿µ¹®
    ÇѱÛ
WordNet ÀÏ¹Ý ¿µ¿µ »çÀü °Ë»ö °á°ú : 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü ¸ÂÃã °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
¿ÜºÎ ¸µÅ© - American Heritage Dictionary ¿µ¿µ»çÀü À¯»ç °Ë»ö (https://www.ahdictionary.com) °á°ú: 0 ÆäÀÌÁö: 6
ÅëÇÕ°Ë»ö ¿Ï·á